News & Events about Mink Therapeutics Inc.
Globe Newswire
2 months ago
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.,a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated ...
Globe Newswire
3 months ago
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a reduction of target and non-target lesions or disease stabilizationFirst immune cell therapy (agenT-797...
Globe Newswire
3 months ago
Conference Call on Thursday, November 3rd, 2022, at 8:30 a.m. ETNEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT...
Globe Newswire
4 months ago
Experts in disease pathways discuss clinical data of allo-iNKTsR&D strategy driving pipeline momentum, productivity, and innovationInternal scalable manufacturing of fully allogeneic iNKT cells; expanded capacity to ~700,000 dosesR&D event: November 10th from 4:00-6:00 pm ET, Boston, MA, and webcast...